The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973. The Cancer Letter provides authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. Our coverage focuses on the National Cancer Institute, National Institutes of Health, Food & Drug Administration, U.S. Congress, cancer centers, and the pharmaceutical industry. The Cancer Letter’s readers include key opinion leaders at academic institutions, community oncology practices, government agencies, professional associations, health IT and pharmaceutical companies, Wall Street, and advocacy organizations. Based in Washington, D.C., The Cancer Letter has earned acclaim for its investigative work. It has been profiled and cited in outlets including The New York Times, The Washington Post, 60 Minutes, CNN, NPR, Science, and Nature. Coverage by The Cancer Letter has triggered multiple investigations by Congressional committees, the Institute of Medicine, the Federal Trade Commission, the Securities and Exchange Commission, and the Department of Justice, and contributed to federal action by the FDA, the Centers for Disease Control and Prevention, the Federal Bureau of Investigation, and Government Accountability Office.
